MD 101 / MaimoniDex RA - LARVOL DELTA

An open, phase Ia safety and dosing clinical trial evaluating IMD-101 in participants with advanced solid tumours. (ANZCTR) - P1 | N=30 | Not yet recruiting | Sponsor: Catalysis Therapeutics Pty Ltd

Metastases • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Yoga as Adjunct Therapy for Chronic Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Avicenna J Med) - "The meta-analysis showed that yoga was associated with significant improvements in peak VO (mean difference [MD]= 3.29; 95% Confidence Interval [CI]: 1.64 to 4.94; I = 0%), exercise capacity (MD=101.54; 95% CI: 6.24 to 196.83; I = 96%), quality of life (MD = -19.99; 95% CI: -25.76 to -14.22; I  = 43%), NT-proBNP (MD = -288.78; 95% CI: -492.20 to -85.37; I  = 94%), and 6-minute walk test (MD = 101.54; 95% CI: 6.24-196.83; I  = 96%), but not in the left ventricular ejection fraction (MD = 4.28; 95% CI: -1.14 to 9.70; I  = 93%)...However, the low-quality evidence does not render us to conclude anything beyond doubt or draw any firm clinical recommendation. Future high-quality studies are needed to explore the optimal duration and frequency of yoga practice and its effects on long-term outcomes in this population."

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

EFFECT OF PROBIOTICS TREATMENT ON PHYSICAL AND MENTAL ASPECTS FOR PATIENTSWITH CORONARY ARTERY DISEASE: A META-ANALYSIS (ACC-WCC 2023) - "Our findings highlight the probiotics treatment for patients with CAD, probiotics treatment can not only improve the physical but also mental aspects. It has a positive therapeutic effect on the treatment of CAD."

Retrospective data • Cardiovascular • CNS Disorders • Coronary Artery Disease • Depression • Dyslipidemia • Immunology • Inflammation • Psychiatry • CRP

TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms (clinicaltrials.gov) - P1/2 | N=9 | Terminated | Sponsor: Medigene AG | N=92 ➔ 9 | Trial completion date: Apr 2024 ➔ Jul 2022 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2020 ➔ Jun 2022; The clinical trial is terminated after the completion of phase I without moving to Phase II.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology • HLA-A • PRAME

Telerehabilitation improves physical function and reduces dyspnoea in people with COVID-19 and post-COVID-19 conditions: a systematic review. (PubMed, J Physiother) - "Telerehabilitation may improve functional capacity, dyspnoea, performance and physical components of quality of life and does not substantially increase adverse events."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease

Is Piezocision effective in accelerating orthodontic tooth movement: A systematic review and meta-analysis. (PubMed, PLoS One) - "Low quality evidence suggests that piezocision is an effective surgical procedure in accelerating the rate of canine retraction in the first two months and reducing the treatment duration. However, this effect appears to be clinically insignificant."

Journal • Retrospective data • Review

TCR Modified T Cells MDG1011in High Risk Myeloid and Lymphoid Neoplasms (clinicaltrials.gov) - P1/2; N=92; Recruiting; Sponsor: Medigene AG; Trial completion date: Apr 2023 ➔ Apr 2024; Trial primary completion date: Aug 2019 ➔ Aug 2020

Clinical • Trial completion date • Trial primary completion date